Breaking News Instant updates and real-time market news.

LXRX

Lexicon

$18.07

0.17 (0.95%)

07:15
10/03/16
10/03
07:15
10/03/16
07:15

Lexicon presents data from TELECAST Phase 3 study at NANETS

Lexicon Pharmaceuticals announced that data from its TELECAST Phase 3 study were presented at the 2016 Annual Symposium of the North American Neuroendocrine Tumor Society, held September 30 to October 1 in Jackson, Wyoming, by Dr. Marianne Pavel in a presentation, entitled "Efficacy and Safety Results of Telotristat Ethyl in Patients with Carcinoid Syndrome During the Double-blind Treatment Period of the TELECAST Phase 3 Clinical Trial." Safety and tolerability was one of the primary objectives of the TELECAST study, and telotristat ethyl was well tolerated during the double-blind treatment period. Across all three treatment arms (placebo, 250 mg, 500 mg, each taken three times daily), the incidence of treatment-emergent adverse events were 80.8%, 100% and 84.0%, respectively; the incidence of serious AEs were 19.2%, 4.0% and 8.0%, respectively; and discontinuation due to AEs were 3.8%, 8.0% and 0%, respectively. AEs of depression or depressed mood were seen in two patients (7.7%) in the placebo arm and one (4.0%) in each of the telotristat ethyl treatment arms. Gastrointestinal AEs were seen in 57.7%, 64.0% and 36.0% of patients in the placebo, 250 mg and 500 mg treatment arms, respectively. Telotristat ethyl met the study's primary efficacy endpoint, the percent change from baseline in urinary 5-hydroxyindoleacetic acid (5-HIAA, the main metabolite of serotonin) at week 12, the final week of the double-blind treatment portion of the study (pless than0.001 for both telotristat ethyl arms compared to placebo). The placebo-adjusted change in 5-HIAA was -54.0% and -89.7% for the 250 mg and 500 mg treatment arms, respectively. In addition, despite the lower baseline bowel movement frequency than in TELESTAR, telotristat ethyl achieved statistically significant reductions in daily bowel movement frequency over the 12 weeks of the study (p=0.004 for the 250 mg treatment arm and pless than0.001 for the 500 mg treatment arm compared to placebo). Baseline mean daily bowel movement frequency was 2.2, 2.5 and 2.8 in the placebo, 250 mg and 500 mg arms. Patients in the 250 mg and 500 mg dose arms experienced noteworthy reductions in daily bowel movement frequency early in the study that tended to increase over time. The placebo-adjusted reduction in daily bowel movement frequency over the entire 12-week period was -0.45 and -0.54 for the 250 mg and 500 mg treatment arms, respectively. Notably, 40% of patients in each of the telotristat ethyl treatment arms achieved a greater than or equal to30% reduction in BM frequency for at least 50% of the days in the double-blind treatment period, while not a single patient in the placebo arm achieved that result (p=0.001 for both doses compared to placebo).

  • 30

    Nov

  • 28

    Feb

LXRX Lexicon
$18.07

0.17 (0.95%)

05/05/16
COWN
05/05/16
INITIATION
COWN
Market Perform
Lexicon coverage assumed with a Market Perform at Cowen
05/31/16
WEDB
05/31/16
NO CHANGE
Target $30
WEDB
Outperform
Lexicon price target raised to $30 from $28 at Wedbush
Wedbush analyst Liana Moussatos increased the firm's multiple on peak telotristat etiprate sales to 8x from 7x to reflect the reduced risk following the FDA's acceptance of the New Drug Application and raised the firm's price target accordingly to $30 from $28. Wedbush maintains its Outperform rating on Lexicon shares.
08/02/16
SBSH
08/02/16
INITIATION
Target $21
SBSH
Buy
Lexicon initiated with a Buy at Citi
Citi analyst Yigal Nochomovitz started Lexicon Pharmaceuticals with a Buy rating and $21 price target. The analyst expects "timely approval and launch" of the company's lead drug telotristat etiprate, an add-on to standard of care to treat severe diarrhea in carcinoid syndrome patients. He believes this should provide near-term support for the stock.
09/12/16
SBSH
09/12/16
NO CHANGE
Target $25
SBSH
Buy
Lexicon price target raised to $25 from $21 at Citi
Citi analyst Yigal Nochomovitz raised his price target for Lexicon Pharmaceuticals to $25 saying sotagliflozin showed "strong efficacy" in its first Phase 3 trial in Type 1 diabetes mellitus. The analyst believes concerns over Sotagliflozin safety should be lifted on these data. He reiterates a Buy rating on Lexicon.

TODAY'S FREE FLY STORIES

BBBY

Bed Bath & Beyond

$27.03

-0.27 (-0.99%)

16:50
09/19/17
09/19
16:50
09/19/17
16:50
Technical Analysis
Technical View: Bed Bath & Beyond tumbles after earnings miss expectations »

The stock was last down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

ADBE

Adobe

$156.60

0.83 (0.53%)

16:48
09/19/17
09/19
16:48
09/19/17
16:48
Earnings
Adobe sees Q4 adjusted EPS of about $1.15, consensus $1.10 »

Sees Q4 revenue about…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

  • 22

    Oct

VNO

Vornado

$73.37

-1.19 (-1.60%)

16:48
09/19/17
09/19
16:48
09/19/17
16:48
Hot Stocks
Vornado provides information regarding its investment in Toys 'R Us »

Vornado announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ORIG

Ocean Rig UDW

$0.16

-0.0083 (-4.90%)

16:47
09/19/17
09/19
16:47
09/19/17
16:47
Hot Stocks
Ocean Rig UDW announces 1-for-9,200 reverse stock split »

Ocean Rig UDW announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AXAR

Axar Acquisition Corp

16:45
09/19/17
09/19
16:45
09/19/17
16:45
Hot Stocks
Axar Acquisition announces redemption of outstanding shares and dissolution »

Axar Acquisition…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BBBY

Bed Bath & Beyond

$27.03

-0.27 (-0.99%)

16:44
09/19/17
09/19
16:44
09/19/17
16:44
Hot Stocks
Breaking Hot Stocks news story on Bed Bath & Beyond »

Bed Bath & Beyond…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

BBU

Brookfield Business Partners

$31.08

0.08 (0.26%)

, BAM

Brookfield

$40.14

0.02 (0.05%)

16:40
09/19/17
09/19
16:40
09/19/17
16:40
Syndicate
Brookfield Business Partners announces $600M equity offering »

Brookfield Business…

BBU

Brookfield Business Partners

$31.08

0.08 (0.26%)

BAM

Brookfield

$40.14

0.02 (0.05%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MXWL

Maxwell

$6.29

-0.24 (-3.68%)

16:40
09/19/17
09/19
16:40
09/19/17
16:40
Syndicate
Maxwell files to sell $50M of convertible senior notes due 2022 »

Maxwell Technologies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IOVA

Iovance Biotherapeutics

$8.55

0.3 (3.64%)

16:38
09/19/17
09/19
16:38
09/19/17
16:38
Syndicate
Iovance Biotherapeutics files to sell $50M of common stock »

Jefferies and Wells…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

FB

Facebook

$172.52

2.51 (1.48%)

16:37
09/19/17
09/19
16:37
09/19/17
16:37
Periodicals
Facebook public hearing will happen according to Senator Burr, Bloomberg says »

According to Bloomberg,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

ELS

Equity Lifestyle

$87.87

-0.23 (-0.26%)

16:35
09/19/17
09/19
16:35
09/19/17
16:35
Hot Stocks
Equity Lifestyle provides update on Hurricane Irma impact, reaffirms guidance »

Equity LifeStyle…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

  • 30

    Jan

BBBY

Bed Bath & Beyond

$27.03

-0.27 (-0.99%)

16:35
09/19/17
09/19
16:35
09/19/17
16:35
Hot Stocks
Breaking Hot Stocks news story on Bed Bath & Beyond »

Bed Bath & Beyond…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

MXWL

Maxwell

$6.29

-0.24 (-3.68%)

16:34
09/19/17
09/19
16:34
09/19/17
16:34
Hot Stocks
Maxwell enters into Amended and Restated Agreement with Viex »

Maxwell Technologies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MRCY

Mercury Systems

$48.29

0.84 (1.77%)

16:33
09/19/17
09/19
16:33
09/19/17
16:33
Hot Stocks
Mercury Systems receives $3.8M order for advanced electronic warfare application »

Mercury Systems announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HF

HFF Inc.

$37.12

0.12 (0.32%)

16:30
09/19/17
09/19
16:30
09/19/17
16:30
Hot Stocks
HFF Inc. announces sale of office in Raleigh-Durham, NC for $105.5M »

Holliday Fenoglio Fowler…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

16:30
09/19/17
09/19
16:30
09/19/17
16:30
Options
Preliminary option volume of 13.8M today »

Preliminary option volume…

RYAM

Rayonier Advanced Materials

16:30
09/19/17
09/19
16:30
09/19/17
16:30
Hot Stocks
Rayonier Advanced Materials estimates impact from Hurricane Irma »

Rayonier Advanced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ALOG

Analogic

$75.95

-1.35 (-1.75%)

16:28
09/19/17
09/19
16:28
09/19/17
16:28
Earnings
Analogic sees FY18 EPS $2.70 to $2.90, two estimates consensus $2.80 »

Sees FY18 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

AMZN

Amazon.com

$969.86

-4.33 (-0.44%)

, TMUS

T-Mobile

$65.42

3.62 (5.86%)

16:28
09/19/17
09/19
16:28
09/19/17
16:28
General news
On The Fly: Top stock stories for Tuesday »

Stocks searched for a…

AMZN

Amazon.com

$969.86

-4.33 (-0.44%)

TMUS

T-Mobile

$65.42

3.62 (5.86%)

S

Sprint

$8.20

0.52 (6.77%)

VZ

Verizon

$49.34

1.25 (2.60%)

SFTBF

SoftBank

$82.75

4.45 (5.68%)

DTEGY

Deutsche Telekom

$18.75

0.68 (3.76%)

BOBE

Bob Evans

$77.41

4.48 (6.14%)

POST

Post Holdings

$86.36

0.52 (0.61%)

RAD

Rite Aid

$2.40

-0.33 (-12.09%)

WBA

Walgreens Boots Alliance

$81.21

-1.39 (-1.68%)

KSS

Kohl's

$45.38

0.49 (1.09%)

AZO

AutoZone

$535.19

-28.21 (-5.01%)

SNCR

Synchronoss

$9.82

-6.93 (-41.37%)

REV

Revlon

$17.05

1.05 (6.56%)

BBY

Best Buy

$52.76

-4.59 (-8.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

  • 19

    Sep

  • 19

    Sep

  • 21

    Sep

  • 22

    Sep

  • 27

    Sep

  • 28

    Sep

  • 02

    Oct

  • 19

    Oct

  • 22

    Oct

  • 30

    Oct

  • 09

    Nov

  • 16

    May

FDX

FedEx

$216.00

0.92 (0.43%)

16:26
09/19/17
09/19
16:26
09/19/17
16:26
Earnings
FedEx sees FY18 ex-items EPS $12.00-$12.80, consensus $13.38 »

The company is lowering…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

  • 21

    Sep

  • 25

    Sep

CSTM

Constellium

$10.00

0.4 (4.17%)

16:26
09/19/17
09/19
16:26
09/19/17
16:26
Hot Stocks
Constellium signs contract with Pilatus to support jet aircraft program »

Constellium announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

  • 02

    Oct

GEMP

Gemphire Therapeutics

$9.65

0.54 (5.93%)

16:25
09/19/17
09/19
16:25
09/19/17
16:25
Conference/Events
Gemphire Therapeutics to hold a conference call »

Management discusses…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

  • 25

    Sep

SERV

ServiceMaster

$47.06

0.1 (0.21%)

16:23
09/19/17
09/19
16:23
09/19/17
16:23
Initiation
ServiceMaster initiated  »

ServiceMaster initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HSC

Harsco

$19.90

0.4 (2.05%)

16:22
09/19/17
09/19
16:22
09/19/17
16:22
Hot Stocks
Harsco gets orders from D.C and Sacramento, CA for safety systems »

Harsco Corporation's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 26

    Sep

SBRA

Sabra Health Care

$22.97

-0.47 (-2.01%)

, TPGI

Now owned by PKY

16:22
09/19/17
09/19
16:22
09/19/17
16:22
Hot Stocks
Sabra to acquire 49% equity interest in senior housing managed by Enlivant »

Sabra Health Care,…

SBRA

Sabra Health Care

$22.97

-0.47 (-2.01%)

TPGI

Now owned by PKY

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.